Cited by 4,427Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesHematopoietic Stem Cell Transplantation

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Open access

Greenberg, Peter, Cox, Christopher, LeBeau, Michelle M., Fenaux, Pierre, Morel, Pierre, Sanz, Guillermo, Sanz, Miguel, Vallespi, Teresa, Hamblin, Terry, Oscier, David, Ohyashiki, Kazuma, Toyama, Keisuke, Aul, Carlo, Mufti, Ghulam, Bennett, John·1997·Blood

DOI 10.1182/blood.v89.6.2079

Open this paper in CoChat — free account Open PDF

Abstract

Despite multiple disparate prognostic risk analysis systems for evaluating clinical outcome for patients with myelodysplastic syndrome (MDS), imprecision persists with such analyses. To attempt to improve on these systems, an International MDS Risk Analysis Workshop combined cytogenetic, morphological, and clinical data from seven large previously reported risk-based studies that had generated prognostic systems. A global analysis was performed on these patients, and critical prognostic variables were re-evaluated to generate a consensus prognostic system, particularly using a more refined bone marrow (BM) cytogenetic classification. Univariate analysis indicated that the major variables having an impact on disease outcome for evolution to acute myeloid leukemia were cytogenetic abnormalities, percentage of BM myeloblasts, and number of cytopenias; for survival, in addition to the above, variables also included age and gender. Cytogenetic subgroups of outcome were as follows: “good” outcomes were normal, −Y alone, del(5q) alone, del(20q) alone; “poor” outcomes were complex (ie, ≥3 abnormalities) or chromosome 7 anomalies; and “intermediate” outcomes were other abnormalities. Multivariate analysis combined these cytogenetic subgroups with percentage of BM blasts and number of cytopenias to generate a prognostic model. Weighting these variables by their statistical power separated patients into distinctive subgroups of risk for 25% of patients to undergo evolution to acute myeloid leukemia, with: low (31% of patients), 9.4 years; intermediate-1 (INT-1; 39%), 3.3 years; INT-2 (22%), 1.1 years; and high (8%), 0.2 year. These features also separated patients into similar distinctive risk groups for median survival: low, 5.7 years; INT-1, 3.5 years; INT-2, 1.2 years; and high, 0.4 year. Stratification for age further improved analysis of survival. Compared with prior risk-based classifications, this International Prognostic Scoring System provides an improved method for evaluating prognosis in MDS. This classification system should prove useful for more precise design and analysis of therapeutic trials in this disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood.v89.6.2079

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

International System for Human Cytogenetic Nomenclature
National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,831
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,619
Self-citation
Myelodysplastic syndromes: a scoring system with prognostic significance
Mufti, G. J., Stevens, J. R., Oscier, D. G., Hamblin, T. J., & Machin, D. (1985) · British Journal of Haematology · doi:10.1111/j.1365-2141.1985.tb07329.x · Cited by 507
Self-citation
The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., Sultan, C., & Cox, C. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb06734.x · Cited by 431
Self-citation
Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients
Sanz, G. F., Sanz, M. Á., Vallespı́, T., Cañizo, M., Torrabadella, M., Garcia, S., Irriguible, D., & Miguel, J. F. S. (1989) · Blood · doi:10.1182/blood.v74.1.395.395 · Cited by 406
Self-citation
The 5q− anomaly
BERGHE, H. V. D., Vermaelen, K., Mecucci, C., Barbieri, D., & Tricot, G. J. K. (1985) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(85)90016-0 · Cited by 322
Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel, P., Hebbar, M., Laï, J. L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F., & Fenaux, P. (1993) · PubMed · Cited by 300
Self-citation
Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Aul, C., Gattermann, N., Heyll, A., Germing, U., Derigs, G., & Schneider, W. (1992) · PubMed · Cited by 265
Self-citation
Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes
Rh, J., Cornbleet, M., Vardiman, J., Larson, R. A., Beau, M. M. L., & Rowley, J. (1986) · Blood · doi:10.1182/blood.v67.6.1765.1765 · Cited by 246
Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia
Yunis, J. J., Lobell, M., Arnesen, M. A., Oken, M. M., Mayer, M. G., Rydell, R. E., & Brunning, R. D. (1988) · British Journal of Haematology · doi:10.1111/j.1365-2141.1988.tb06188.x · Cited by 232

Show all 33 references

Sorted by citations

Items 401–500 of 1,003

The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes
Zorat, F., Shetty, V. T., Dutt, D., Lisak, L., Nascimben, F., Allampallam, K., Dar, S., York, A., Gezer, S., Venugopal, P., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03204.x · Cited by 108
Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients
Terpos, E., Mougiou, A., Kouraklis, A., Chatzivassili, A., Michalis, E., Giannakoulas, N., Manioudaki, E., Lazaridou, A., Bakaloudi, V., Protopappa, M., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03583.x · Cited by 108
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial
Stein, E. M., Fathi, A. T., Dinardo, C. D., Pollyea, D. A., Roboz, G. J., Collins, R. H., Sekeres, M. A., Stone, R. M., Attar, E. C., Frattini, M. G., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30284-4 · Cited by 109
Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers
Naqvi, K., Jabbour, E. J., Bueso-Ramos, C., Pierce, S. A., Borthakur, G. M., Estrov, Z. E., Ravandi, F., Faderl, S. H., Kantarjian, H. M., & Garcia‐Manero, G. (2011) · Blood · doi:10.1182/blood-2011-03-342642 · Cited by 107
Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes
Sekeres, M. A., Maciejewski, J. P., Giagounidis, A. A. N., Wride, K., Knight, R., Raza, A., & List, A. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5770 · Cited by 107
Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes
Garcia‐Manero, G., Montalban‐Bravo, G., Berdeja, J. G., Abaza, Y., Jabbour, E., Essell, J., Lyons, R. M., Ravandi, F., Maris, M., Heller, B., et al. (2017) · Cancer · doi:10.1002/cncr.30533 · Cited by 104
Epigenetic Changes in the Myelodysplastic Syndrome
Issa, J. J. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.02.007 · Cited by 110
Flow cytometry in myelodysplastic syndromes: Report from a working conference
Loken, M. R., van de Loosdrecht, A. A., Ogata, K., Órfão, A., & Wells, D. A. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.04.020 · Cited by 106
Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Kröger, N. M., Zabelina, T., Guardiola, P., Runde, V., Sierra, J., van Biezen, A., Niederwieser, D. W., Zander, A. R., & de Witte, T. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03552.x · Cited by 106
Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes
Matsuda, A., Germing, U., Jinnai, I., Misumi, M., Kuendgen, A., Knipp, S., Aivado, M. A., Iwanaga, M., Miyazaki, Y., Tsushima, H., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0040 · Cited by 106
18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment.
Agool, A., Schot, B. W., Jager, P. L., & Vellenga, E. (2006) · PubMed · Cited by 106
Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients
Jilg, S., Reidel, V., Müller‐Thomas, C., König, J., Schauwecker, J., Höckendorf, U., Huberle, C., Gorka, O., Schmidt, B., Burgkart, R., et al. (2015) · Leukemia · doi:10.1038/leu.2015.179 · Cited by 106
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia
Daver, N. G., Strati, P., Jabbour, E. J., Kadia, T. M., Luthra, R., Wang, S., Patel, K. P., Ravandi, F., Cortes, J. E., Dong, X. Q., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23345 · Cited by 110
International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes
Kao, J. M., McMillan, A., & Greenberg, P. L. (2008) · American Journal of Hematology · doi:10.1002/ajh.21249 · Cited by 103
Self-citation
Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant
Wang, Y., Wang, H.-X., Lai, Y.-R., Sun, Z.-M., Wu, D., Jiang, M., Liu, D.-H., Xu, K.-L., Liu, Q.-F., Liu, L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.110 · Cited by 105
Mutations of myelodysplastic syndromes (MDS): An update
Ganguly, B. B., & Kadam, N. N. (2016) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.04.009 · Cited by 108
Azacitidine for the treatment of lower risk myelodysplastic syndromes
Musto, P., Maurillo, L., Spagnoli, A., Gozzini, A., Rivellini, F., Lunghi, M., Villani, O., Spiriti, M. A. A., Venditti, A., & Santini, V. (2010) · Cancer · doi:10.1002/cncr.24894 · Cited by 107
Therapy-Related Myelodysplastic Syndrome
Singh, Z. N., Huo, D., Anastasi, J., Smith, S. M., Karrison, T. G., Beau, M. M. L., Larson, R. A., & Vardiman, J. W. (2007) · American Journal of Clinical Pathology · doi:10.1309/nq3pmv4u8yv39jwj · Cited by 105
Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes
Tehranchi, R. (2005) · Blood · doi:10.1182/blood-2004-12-4649 · Cited by 104
Clofarabine ± Fludarabine with Once Daily i.v. Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS
Andersson, B. S., Valdez, B. C., de Lima, M., Wang, X., Thall, P. F., Worth, L. L., Popat, U., Madden, T. L., Hosing, C. M., Alousi, A. M., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.09.022 · Cited by 104
An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients
Wijermans, P., Lübbert, M., Verhoef, G. E. G., Klimek, V. M., & Bosly, A. (2005) · Annals of Hematology · doi:10.1007/s00277-005-0012-1 · Cited by 104
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome
Fenaux, P., Raza, A., Mufti, G. J., Aul, C., Germing, U., Kantarjian, H. M., Cripe, L. D., Kerstens, R., Porre, P. D., & Kurzrock, R. (2007) · Blood · doi:10.1182/blood-2006-07-035725 · Cited by 104
Self-citation
Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses
Loken, M. R., Chu, S., Fritschle, W. K., Kalnoski, M. H., & Wells, D. A. (2008) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.20429 · Cited by 104
Accommodating haploinsufficient tumour suppressor genes in Knudson's model
Cook, W. D., & McCaw, B. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203653 · Cited by 104
Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study
Deeg, H. J., Gotlib, J. R., Beckham, C., Dugan, K., Holmberg, L., Schubert, M., Appelbaum, F. R., & Greenberg, P. L. (2002) · Leukemia · doi:10.1038/sj.leu.2402356 · Cited by 104
Self-citation
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)
Saber, W., Cutler, C. S., Nakamura, R., Zhang, M., Atallah, E. L., Rizzo, J. D., Maziarz, R. T., Cortes, J. E., Kalaycio, M. E., & Horowitz, M. M. (2013) · Blood · doi:10.1182/blood-2013-04-496778 · Cited by 104
Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome
Zuo, Z., Calin, G. A., de Paula, H. M., Medeiros, L. J., Fernandez, M. H., Shimizu, M., Garcia‐Manero, G., & Bueso-Ramos, C. (2011) · Blood · doi:10.1182/blood-2011-01-330704 · Cited by 103
Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis
Messa, E., Cilloni, D., Messa, F., Arruga, F., Roetto, A., & Saglio, G. N. (2008) · Acta Haematologica · doi:10.1159/000158631 · Cited by 103
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study
Stauder, R., Yu, G., Koinig, K. A., Bagguley, T., Fenaux, P., Symeonidis, A. S., Sanz, G. F., Čermák, J., Mittelman, M., Hellström‐Lindberg, E., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0089-x · Cited by 103
Self-citation
Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring
Xu, F., Li, X., Wu, L., Zhang, Q., Yang, R., Yang, Y., Zhang, Z., He, Q., & Chang, C. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1128-5 · Cited by 103
RUNX1 Mutations in Clonal Myeloid Disorders: From Conventional Cytogenetics to Next Generation Sequencing, A Story 40 Years in the Making
Mangan, J. K., & Speck, N. A. (2011) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v16.i1-2.80 · Cited by 103
Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome
Lee, J.-H., Lee, J.-H., Shin, Y.-R., Js, L., Kim, W., Chi, H.-S., Park, C.-J., Ej, S., & Lee, K.-H. (2003) · Leukemia · doi:10.1038/sj.leu.2402798 · Cited by 103
Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine
Borthakur, G. M., Ahdab, S. E., Ravandi, F., Faderl, S. H., Ferrajoli, A., Newman, B., Issa, J. J., & Kantarjian, H. M. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701882146 · Cited by 103
How we treat higher-risk myelodysplastic syndromes
Sekeres, M. A., & Cutler, C. S. (2013) · Blood · doi:10.1182/blood-2013-08-496935 · Cited by 102
Clinical and genetic predictors of prognosis in myelodysplastic syndromes
Bejar, R. L. (2014) · Haematologica · doi:10.3324/haematol.2013.085217 · Cited by 107
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial
Kantarjian, H. M., Fenaux, P., Sekeres, M. A., Szer, J., Platzbecker, U., Kuendgen, A., Gaïdano, G., Wiktor-Jędrzejczak, W., Carpenter, N., Mehta, B., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30016-4 · Cited by 102
Self-citation
Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)
Kröger, N., Sockel, K., Wolschke, C., Bethge, W. A., Schlenk, R. F., Wolf, D. G. F., Stadler, M., Kobbe, G., Wulf, G. G., Bug, G., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02724 · Cited by 102
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes
Voso, M. T., Santini, V., Finelli, C., Musto, P., Pogliani, E., Angelucci, E., Fioritoni, G., Alimena, G., Maurillo, L., Cortelezzi, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0494 · Cited by 102
Loss of Mll5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation
Heuser, M., Yap, D., Leung, M., de Algara, T. R., Tafech, A., McKinney, S. E., Dixon, J., Thresher, R. R., Colledge, B., Carlton, M. B. L., et al. (2008) · Blood · doi:10.1182/blood-2008-06-162263 · Cited by 102
Clinical Relevance of Anemia and Transfusion Iron Overload in Myelodysplastic Syndromes
Cazzola, M., Porta, M. G. D., & Malcovati, L. (2008) · Hematology · doi:10.1182/asheducation-2008.1.166 · Cited by 103
Prognostic factors and scoring systems in myelodysplastic syndromes.
Sanz, G. F., Sanz, M. Á., & Greenberg, P. L. (1998) · PubMed · Cited by 102
Self-citation
High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival
Starczynowski, D. T., Vercauteren, S., Telenius, A., Sung, S., Tohyama, K., Brooks-Wilson, A. R., Spinelli, J. J., Eaves, C. J., Eaves, A. C., Horsman, D. E., et al. (2008) · Blood · doi:10.1182/blood-2007-11-122028 · Cited by 101
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency
Grossman, J. K., Cuellar‐Rodríguez, J., Gea‐Banacloche, J., Zerbe, C. S., Calvo, K. R., Hughes, T. E., Hakim, F. T., Cole, K. M., Parta, M., Freeman, A. F., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.08.004 · Cited by 101
Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Nemecek, E. R., Guthrie, K. A., Sorror, M. L., Wood, B. L., Doney, K., Hilger, R. A., Scott, B. L., Kovacsovics, T. J., Maziarz, R. T., Woolfrey, A. E., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.05.007 · Cited by 101
High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study
Mannone, L., Gardin, C., Quarré, M. C., Bernard, J. F., Vassilieff, D., Adès, L., Park, S., Vaultier, S., Hamza, F., Beyne‐rauzy, M. O., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06070.x · Cited by 100
Self-citation
Iron overload in MDS—pathophysiology, diagnosis, and complications
Gattermann, N., & Rachmilewitz, E. A. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1091-1 · Cited by 101
Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): Results of a large internet-based survey
Steensma, D. P., Heptinstall, K. V., Johnson, V. M., Novotny, P. J., Sloan, J. A., Camoriano, J. K., Niblack, J., Bennett, J. M., & Mesa, R. A. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.10.015 · Cited by 101
Self-citation
Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer
Ebert, B. L. (2009) · Leukemia · doi:10.1038/leu.2009.53 · Cited by 101
Myelodysplastic Syndromes in Patients Younger Than Age 50
Kuendgen, A., Strupp, C., Aivado, M. A., Hildebrandt, B., Haas, R. R., Gattermann, N., & Germing, U. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.5598 · Cited by 101
Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia
Matsushima, T., Handa, H., Yokohama, A., Nagasaki, J., Koiso, H., Kin, Y., Tanaka, Y., Sakura, T., Tsukamoto, N., Karasawa, M., et al. (2003) · Blood · doi:10.1182/blood-2002-03-0947 · Cited by 101
Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony‐stimulating factor and erythropoietin
Mantovani, L., Lentini, G., Hentschel, B., Wickramanayake, P. D., Loeffler, M., Diehl, V., & Tesch, H. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02016.x · Cited by 101
Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review
Patnaik, M. M., Parikh, S. A., Hanson, C. A., & Tefferi, A. (2014) · British Journal of Haematology · doi:10.1111/bjh.12756 · Cited by 99
Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis
Fenaux, P., Kiladjian, J., & Platzbecker, U. (2019) · Blood · doi:10.1182/blood-2018-11-876888 · Cited by 100
Self-citation
Current challenges and unmet medical needs in myelodysplastic syndromes
Platzbecker, U., Kubasch, A. S., Homer-Bouthiette, C., & Prébet, T. (2021) · Leukemia · doi:10.1038/s41375-021-01265-7 · Cited by 103
Pathobiology, classification, and diagnosis of myelodysplastic syndrome
Mufti, G. J. (2004) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2004.08.007 · Cited by 100
Self-citation
Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan
Sasaki, H., Manabe, A., Kojima, S., Tsuchida, M., Hayashi, Y., Ikuta, K., Okamura, J., Koike, K., Ohara, A., Ishii, E., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402271 · Cited by 100
SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function
Sun, J., He, X., Zhu, Y., Ding, Z., Dong, H., Feng, Y., Du, J., Wang, H., Wu, X., Zhang, L., et al. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.07.018 · Cited by 99
How we manage adults with myelodysplastic syndrome
Fenaux, P., Platzbecker, U., & Adès, L. (2019) · British Journal of Haematology · doi:10.1111/bjh.16206 · Cited by 103
Self-citation
Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: A pilot study on a series of 56 patients
Matarraz, S., López, A., Bárrena, S., Fernández, C., Jensen, E., Flores-Montero, J. A., Rasillo, A., Sayagués, J. M., Sánchez, M. L., Bárcena, P., et al. (2010) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.20513 · Cited by 99
Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients
Nyåkern, M., Tazzari, P. L., Finelli, C., Bosi, C., Follo, M. Y., Grafone, T., Piccaluga, P. P., Martinelli, G., Cocco, L., & Martelli, A. M. (2005) · Leukemia · doi:10.1038/sj.leu.2404057 · Cited by 99
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML
Löwenberg, B., Pabst, T., Maertens, J. A., van Norden, Y., Biemond, B. J., Schouten, H. C., Spertini, O., Vellenga, E., Graux, C., Havelange, V., et al. (2017) · Blood · doi:10.1182/blood-2016-10-740613 · Cited by 98
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents
Park, S., Hamel, J.-F., Toma, A., Kelaïdi, C., Thépot, S., Díez‐Campelo, M., Santini, V., Sekeres, M. A., Balleari, E., Kaivers, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3271 · Cited by 98
Self-citation
Oxidative Stress and the Myelodysplastic Syndromes
Farquhar, M. J., & Bowen, D. (2003) · International Journal of Hematology · doi:10.1007/bf02982641 · Cited by 96
Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes
Paulsson, K. M., & Johansson, B. (2006) · Pathologie Biologie · doi:10.1016/j.patbio.2006.04.007 · Cited by 98
Systemic and immune manifestations in myelodysplasia: A multicenter retrospective study
de Hollanda, A., Beucher, A., Henrion, D., Ghali, A., Lavigne, C., Levesque, H., Hamidou, M., Subra, J., Ifrah, N., & Belizna, C. C. (2011) · Arthritis Care & Research · doi:10.1002/acr.20504 · Cited by 98
Long‐term follow‐up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome
Kantarjian, H. M., Beran, M., Cortes, J. E., O'Brien, S. M., Giles, F. J., Pierce, S. A., Shan, J., Plunkett, W. K., Keating, M. J., & Estey, E. H. (2006) · Cancer · doi:10.1002/cncr.21699 · Cited by 98
Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes.
Ohyashiki, J. H., Iwama, H., Yahata, N., Ando, K., Hayashi, S., Shay, J. W., & Ohyashiki, K. (1999) · PubMed · Cited by 98
Self-citation
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
Pleyer, L., Burgstaller, S., Girschikofsky, M., Linkesch, W., Stauder, R., Pfeilstöcker, M., Schreder, M., Tinchon, C., Sliwa, T., Lang, A. H., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2126-9 · Cited by 97
Predicting response to epigenetic therapy
Treppendahl, M. B., Kristensen, L. S., & Grønbæk, K. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69737 · Cited by 97
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival
Corradi, G., Baldazzi, C., Očadlíková, D., Marconi, G., Parisi, S., Testoni, N., Finelli, C., Cavo, M., Curti, A., & Ciciarello, M. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1013-z · Cited by 102
Decitabine in the treatment of myelodysplastic syndromes.
Saba, H. I. (2007) · PubMed Central · Cited by 97
The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML)
Hasle, H., Baumann, I., Bergsträßer, E., Fenu, S., Fischer, A., Kardos, G., Kerndrup, G. B., Locatelli, F., Rogge, T., Schultz, K. R., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403489 · Cited by 97
Immunophenotyping of acute leukemias and myelodysplastic syndromes
Órfão, A., Ortuño, F. J., de Santiago, M., López, A., & Miguel, J. F. S. (2004) · Cytometry Part A · doi:10.1002/cyto.a.10104 · Cited by 97
Telomeres and telomerase in cancer stem cells
Ju, Z., & Rudolph, K. L. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.040 · Cited by 96
Patient‐related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS ‐ CAN prospective study
Buckstein, R. J., Wells, R. A., Zhu, N. Y., Leitch, H. A., Nevill, T. J., Yee, K. W. L., Leber, B. F., Sabloff, M., St‐Hilaire, È., Kumar, R., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14033 · Cited by 99
Guidelines for the diagnosis and management of adult myelodysplastic syndromes
Killick, S. B., Carter, C., Culligan, D. J., Dalley, C. D., Das-Gupta, E. P., Drummond, M. W., Enright, H., Jones, G. L., Kell, J., Mills, J., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12694 · Cited by 97
Self-citation
Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study
Prébet, T., Sun, Z., Ketterling, R. P., Zeidan, A. M., Greenberg, P. L., Herman, J. G., Juckett, M., Smith, M. R., Malick, L., Paietta, E. M., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13832 · Cited by 99
Self-citation
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
Zeidan, A. M., Knaus, H. A., Robinson, T. M., Towlerton, A. M. H., Warren, E. H., Zeidner, J. F., Blackford, A. L., Duffield, A. S., Rizzieri, D. A., Frattini, M. G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3763 · Cited by 98
Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia
Dickinson, M. J., Cherif, H., Fenaux, P., Mittelman, M., Verma, A. K., Portella, M. S. O., Burgess, P., Ramos, P. M., Choi, J., & Platzbecker, U. (2018) · Blood · doi:10.1182/blood-2018-06-855221 · Cited by 96
Self-citation
MDS overlap disorders and diagnostic boundaries
Tanaka, T. N., & Bejar, R. L. (2019) · Blood · doi:10.1182/blood-2018-10-844670 · Cited by 102
Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome
Chen, T.-C., Hou, H.-A., Chou, W.-C., Tang, J.-L., Kuo, Y.-Y., Chen, C.-Y., Tseng, M.-H., Huang, C.-F., Lai, Y.-J., Chiang, Y.-C., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2013.74 · Cited by 99
Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long‐term blood transfusions
Chacko, J. M., Pennell, D. J., Tanner, M. A., Hamblin, T. J., Wonke, B., Levy, T., Thomas, P., & Killick, S. B. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06695.x · Cited by 96
Self-citation
World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes
BERNASCONI, P. P., Klersy, C., Boni, M., Cavigliano, P. M., Calatroni, S., Giardini, I., Rocca, B., Zappatore, R., Caresana, M., Dambruoso, I., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06537.x · Cited by 96
Role of immune responses in the pathogenesis of low‐risk MDS and high‐risk MDS: implications for immunotherapy
Aggarwal, S., van de Loosdrecht, A. A., Alhan, C., Ossenkoppele, G. J., Westers, T. M., & Bontkes, H. J. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08683.x · Cited by 99
Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes
Stasi, R., Abruzzese, E., Lanzetta, G., Terzoli, E., & Amadori, S. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi400 · Cited by 96
Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome
Steensma, D. P., Dispenzieri, A. A., Moore, S. B., Schroeder, G. S., & Tefferi, A. (2003) · Blood · doi:10.1182/blood-2002-09-2867 · Cited by 96
Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
Tan, P., Wei, A. H., Mithraprabhu, S., Cummings, N. J., Liu, H. B., Perugini, M., Reed, K., Avery, S., Patil, S., Walker, P., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2013.68 · Cited by 95
Causes of death in 2877 patients with myelodysplastic syndromes
Nachtkamp, K., Stark, R., Strupp, C., Kündgen, A., Giagounidis, A. A. N., Aul, C., Hildebrandt, B., Haas, R. R., Gattermann, N., & Germing, U. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2649-3 · Cited by 95
Self-citation
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
Garcia‐Manero, G., Roboz, G. J., Walsh, K. J., Kantarjian, H. M., Ritchie, E. K., Kropf, P. L., O'Connell, C. L., Tibes, R., Lunin, S. D., Rosenblat, T. L., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30029-8 · Cited by 95
The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome
Zipperer, E., Pelz, D., Nachtkamp, K., Kuendgen, A., Strupp, C., Gattermann, N., Haas, R. R., & Germing, U. (2009) · Haematologica · doi:10.3324/haematol.2008.002063 · Cited by 95
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine
Pabst, T., Vellenga, E., van Putten, W., Schouten, H. C., Graux, C., Vekemans, M., Biemond, B. J., Sonneveld, P., Passweg, J. R., Verdonck, L. F., et al. (2012) · Blood · doi:10.1182/blood-2011-11-389841 · Cited by 95
Darbepoetin alpha for the treatment of anaemia in low‐intermediate risk myelodysplastic syndromes
Musto, P., Lanza, F., Balleari, E., Grossi, A., Falcone, A. P., Sanpaolo, G., Bodenizza, C., Scalzulli, P. R., Sala, A. L., Campioni, D., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05288.x · Cited by 95
Isolation and characterization of a novel TP53-inducible gene,TP53TG3
Ng, C. C., Koyama, K., Okamura, S., Kondoh, H., Takei, Y., & Nakamura, Y. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199912)26:4 · Cited by 32
Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome
Thompson, J. A., Gilliland, D. G., Prchal, J. T., Bennett, J. M., Larholt, K. M., Nelson, R. A., Rose, E. H., Dugan, M. H., & the GM/EPO MDS Study Group (2000) · Blood · doi:10.1182/blood.v95.4.1175.004k51_1175_1179 · Cited by 95
Self-citation
Allogeneic Hematopoietic Cell Transplantation in Patients Age 60-70 Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia: Comparison with Patients Lacking Donors Who Received Azacitidine
Platzbecker, U., Schetelig, J., Finke, J., Trenschel, R., Scott, B. L., Kobbe, G., Schaefer‐Eckart, K., Bornhäuser, M., Itzykson, R., Germing, U., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.05.003 · Cited by 94
Self-citation
Deferasirox for transfusion‐dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond ( GIMEMA MDS 0306 T rial)
Angelucci, E., Santini, V., Tucci, A. A. D., Quaresmini, G., Finelli, C., Volpe, A., Quarta, G., Rivellini, F., Sanpaolo, G., Cilloni, D., et al. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12300 · Cited by 94
Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes
Germing, U., Aul, C., Niemeyer, C. M., Haas, R. R., & Bennett, J. M. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0499-3 · Cited by 94
Self-citation
Acute Myeloid Leukemia and Myelodysplastic Syndromes After Radiation Therapy Are Similar to De Novo Disease and Differ From Other Therapy-Related Myeloid Neoplasms
Nardi, V., Winkfield, K. M., Ok, C. Y., Niemierko, A., Kluk, M., Attar, E. C., Garcia‐Manero, G., Wang, S. A., & Hasserjian, R. P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7340 · Cited by 94
NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome
Griffiths, E. A., Srivastava, P., Matsuzaki, J., Brumberger, Z. L., Wang, E. S., Kocent, J., Miller, A., Roloff, G. W., Wong, H. Y., Paluch, B. E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1792 · Cited by 94
Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation.
Abruzzese, E., Radford, J. E., Miller, J. S., Vredenburgh, J. J., Rao, P. N., Pettenati, M. J., Cruz, J. M., Perry, J. J., Amadori, S., & Hurd, D. D. (1999) · PubMed · Cited by 94

Authors: Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G., & Bennett, J.
Affiliations: Tokyo Medical University (JP)
From the Hematology Divisions of Stanford University Medical Center, Stanford, CA; the Rochester Medical Center, Rochester, NY; the University of Chicago, Chicago, IL; Centre Hospitalier Universitaire, Lille, France; Hospital La Fe, Valencia, Spain; Hospital Vall d'Hebron, Barcelona, Spain; the Royal Bournemouth Hospital, Bournemouth, UK; the Tokyo Medical College, Tokyo, Japan; the Heinrich Heine University, Dusseldorf, Germany; and the King's College Hospital, London, UK.
ORCID: Greenberg, Peter
Cox, Christopher
Fenaux, Pierre
Morel, Pierre
Sanz, Guillermo
Sanz, Miguel
Oscier, David
Ohyashiki, Kazuma
Toyama, Keisuke
Mufti, Ghulam
Bennett, John
Venue: Blood
Publisher: American Society of Hematology
Published: 1997-03-15
Volume: 89
Issue: 6
Pages: 2079-2088
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood.v89.6.2079
OpenAlex: W187238933
Cited by: 4,427
References: 33
Citations by year: 2026: 45 · 2025: 69 · 2024: 93 · 2023: 124 · 2022: 131 · 2021: 155 · 2020: 167 · 2019: 144 · 2018: 174 · 2017: 226 · 2016: 183 · 2015: 205 · 2014: 232 · 2013: 253 · 2012: 256
FWCI: 36.61
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords: myelodysplastic syndrome, prognostic score, International Prognostic Scoring System, risk stratification, bone marrow cytogenetics, acute myeloid leukemia transformation, bone marrow blasts, cytopenia, survival, del(5q), del(20q)
MeSH terms: Acute Disease, Adolescent, Adult, Age Factors, Aged, Bone Marrow, Female, Follow-Up Studies, Humans, Leukemia, Myeloid, Male, Middle Aged, Myelodysplastic Syndromes, Prognosis, Sex Factors, Multivariate Analysis, Survival Analysis, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks